Neuroblastoma is a heterogeneous solid tumor that originates extracranially from neuroblasts. Previous research has demonstrated that miR-492 polymorphisms can contribute to cancer susceptibility. However, their specific involvement in susceptibility to neuroblastoma has yet to be fully clarified.
Background and objectives
Neuroblastoma is a heterogeneous solid tumor that originates extracranially from neuroblasts. Previous research has demonstrated that miR-492 polymorphisms can contribute to cancer susceptibility. However, their specific involvement in susceptibility to neuroblastoma has yet to be fully clarified.
In this study, we focused on miRNA-492, which has been reported to be a regulator involved in several gastrointestinal cancers. Previous studies have also suggested that the miRNA-492 G>C rs2289030 polymorphism could impact susceptibility to different types of liver cancers, such as hepatocellular carcinoma.
However, to date, no study has investigated the role of miRNA-492 G>C rs2289030 in the risk of neuroblastoma. We conducted this case-control investigation using samples from Nanjing Children's Hospital, comprising 402 cases and 473 controls. The aim was to evaluate the potential link between miRNA-492 G>C rs2289030 and neuroblastoma susceptibility.
Methods
To address this question, we used the TaqMan method to genotype miR-492 rs2289030 G>C in a cohort of 402 neuroblastoma children and 473 control individuals from Jiangsu Province, China.
Results
All of the cases included in this study were newly confirmed neuroblastoma patients who underwent histopathological diagnosis and had no progressive disease or previous treatments. The location of the patients' neuroblastoma was mainly in the retroperitoneal region (41.54%), mediastinum (29.85%) and adrenal gland (23.13%). International Neuroblastoma Staging System (INSS) staging consisted primarily of stage I (26.87%) and stage IV (25.87%). No significant associations were detected between cases and controls in terms of age (P = 0.100) and gender (P = 0.987).
Conclusions
We present initial evidence indicating that polymorphisms in the miR-492 rs2289030 G>C genotype may not have an impact on the risk of neuroblastoma in individuals from Jiangsu province, China. Additional validation of this evidence with larger samples is required. Ultimately, our study may shed light on the role of miR-492 in this aggressive pediatric tumor.
https://www.xiahepublishing.com/2835-3315/CSP-2023-00025S
The study was recently published in the Cancer Screening and Prevention.
Cancer Screening and Prevention (CSP) publishes high-quality research and review articles related to cancer screening and prevention. It aims to provide a platform for studies that develop innovative and creative strategies and precise models for screening, early detection, and prevention of various cancers. Studies on the integration of precision cancer prevention multiomics where cancer screening, early detection and prevention regimens can precisely reflect the risk of cancer from dissected genomic and environmental parameters are particularly welcome.
